Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Orion Oyj Share Issue/Capital Change 2014

Nov 21, 2014

3232_rns_2014-11-21_d266d897-f05a-48b7-8d12-783ca9f7535a.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

Disclosure 319418

Orion - Company Announcement

6,335 Orion A shares converted into B shares

ORION CORPORATION STOCK EXCHANGE RELEASE 21 NOVEMBER 2014 at 9.30 a.m. EET 6,335 Orion A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 6,335 A shares have been converted into 6,335 B shares. The conversion has been entered into the Trade Register on 21 November 2014. The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 40,612,981 A shares and 100,644,847 B shares. Orion Corporation Olli Huotari Jari Karlson SVP, Corporate Functions CFO Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland Homepage: www.orion.fi Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs. Orion's net sales in 2013 amounted to EUR 1,007 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki. [HUG#1873221]